An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tabrecta

Chemical Namecapmatinib
Dosage FormTablets (oral; 150 mg, 200 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyNovartis
Approval Year2020

Indication

  • Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tabrecta (capmatinib) Prescribing Information.2020Novartis Pharmaceuticals Corporation, East Hanover, NJ
Document TitleYearSource
A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (Stage IIIB/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation (METΔex14).2020Novartis Pharmaceuticals